



Aurobindo Pharma receives approval for Terbinafine Tablets from Health Canada

Aurobindo Pharma Limited is pleased to announce that it has received the approval for its Abbreviated New Drug Submission Terbinafine Tablets 125mg and 250mg from Health Canada

Terbinafine (Terbinafine Hydrochloride) Tablets 125mg and 250mg is the generic equivalent of Novartis Pharmaceutical Canada Inc's Lamisil® Tablets 125mg and 250mg, which is indicated for the treatment of fungal infections of the skin and nails.

This is Aurobindo's 5th product approval from Health Canada.

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 100 countries..

For further information, please contact:

Investor Relations
Aurobindo Pharma Limited
Reg Off: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad
Phone: 040-66725000 / 66725401
Email: ir@aurobindo.com